George Reynolds | CCO
Vitro Software

George Reynolds, CCO, Vitro Software

Mr. Reynolds has over 30 years experience in launching  software companies in the UKI, EMEA and US. Since 2013 he has been responsible for OpenApp’s  rare disease registry business. In 2015 he set up the agreement with Vertex to run the 4,000 patient phase IV clinical trial for Orkambi in Europe. In 2016 OpenApp and Vitro won the €5M European Commission tender to supply the ICT platform for all 24 ERNs. In 2017 George moved to Vitro to take up the position of Chief Commercial Officer. He has extensive Pharma and registry experience in rare diseases such as Haemophilia, Cystic Fibrosis, and Epidermolysis Bullosa. He is currently working with Biogen who have recently received EMA marketing authorization  for Spinraza; a breakthrough treatment for Spinal Muscular Atrophy

back to speakers